Provided by Tiger Fintech (Singapore) Pte. Ltd.

RenovoRx Inc

0.9900
-0.0001-0.01%
Volume:2.39K
Turnover:2.41K
Market Cap:36.18M
PE:-2.50
High:1.03
Open:1.03
Low:0.9900
Close:0.9901
Loading ...

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
11 Feb

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement

GuruFocus.com
·
07 Feb

RenovoRx 11.52M share Spot Secondary priced at $1.05

TIPRANKS
·
07 Feb

BRIEF-Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock

Reuters
·
07 Feb

RenovoRx Inc - Pricing Public Offering of 11,523,810 Shares of Its Common Stock at a Price to Public of $1.05 per Share

THOMSON REUTERS
·
07 Feb

RenovoRx Announces Proposed Public Offering

THOMSON REUTERS
·
07 Feb

Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long

Simply Wall St.
·
23 Jan

RenovoRx announces SCRI Oncology partners enrolling patients for trial

TIPRANKS
·
11 Dec 2024

RenovoRx Initiates Patient Enrollment at Scri Oncology Partners for Ongoing Pivotal Phase Iii Tiger-Pac Clinical Trial in Locally Advanced Pancreatic Cancer

THOMSON REUTERS
·
11 Dec 2024

RenovoRx Receives First Purchase Orders for Its FDA-Cleared Renovocath® Delivery System

THOMSON REUTERS
·
05 Dec 2024

RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial

MT Newswires Live
·
20 Nov 2024

RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial

TIPRANKS
·
20 Nov 2024

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase Iii Tiger-Pac Clinical Trial

THOMSON REUTERS
·
20 Nov 2024

Positive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy Rating

TIPRANKS
·
15 Nov 2024

RenovoRx Q3 EPS $(0.10), Inline

Benzinga
·
14 Nov 2024